Targeting the Tumor Microenvironment in Cancer: Why Hyaluronidase Deserves a Second Look
Tóm tắt
Increased extracellular matrix (ECM) deposition is a characteristic observed in many solid tumors. Increased levels of one ECM component—namely, hyaluronan (HA)—leads to reduced elasticity of tumor tissue and increased interstitial fluid pressure. Multiple initial reports showed that the addition of hyaluronidase (HYAL) to chemotherapeutic regimens could greatly improve efficacy. Unfortunately, the bovine HYAL used in those studies was limited therapeutically by immunologic responses to treatment. Newly developed recombinant human HYAL has recently been introduced into clinical trials. In this article, we describe the role of HA in cancer, methods of targeting HA, and clinical studies performed to date, and we propose that targeting HA could now be an effective treatment option for patients with many different types of solid tumors. Cancer Discovery; 1(4): 291–96. ©2011 AACR.
Từ khóa
Tài liệu tham khảo
Mahadevan, 2007, Tumor-stroma interactions in pancreatic ductal adenocarcinoma, Mol Cancer Ther, 6, 1186, 10.1158/1535-7163.MCT-06-0686
Maitra, 2009, Nab®-paclitaxel targets tumor stroma and results, combined with gemcitabine, in high efficacy against pancreatic cancer models (Abstract C246), Mol Cancer Ther, 8, C246, 10.1158/1535-7163.TARG-09-C246
Olive, 2009, Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer, Science, 324, 1457, 10.1126/science.1171362
Bertrand, 1992, Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: comparison between invasive and non-invasive areas, Int J Cancer, 52, 1, 10.1002/ijc.2910520102
Gebhardt, 2010, Dermal hyaluronan is rapidly reduced by topical treatment with glucocorticoids, J Invest Dermatol, 130, 141, 10.1038/jid.2009.210
Yoshihara, 2005, A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells, FEBS Lett, 579, 2722, 10.1016/j.febslet.2005.03.079
Lokeshwar, 2010, Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells, Cancer Res, 70, 2613, 10.1158/0008-5472.CAN-09-3185
Kohno, 1994, Effects of hyaluronidase on doxorubicin penetration into squamous carcinoma multicellular tumor spheroids and its cell lethality, J Cancer Res Clin Oncol, 120, 293, 10.1007/BF01236386
Beckenlehner, 1992, Hyaluronidase enhances the activity of Adriamycin in breast cancer models in vitro and in vivo, J Cancer Res Clin Oncol, 118, 591, 10.1007/BF01211802
Muckenschnabel, 1996, Hyaluronidase pretreatment produces selective melphalan enrichment in malignant melanoma implanted in nude mice, Cancer Chemother Pharmacol, 38, 88, 10.1007/s002800050452
Baumgartner, 1998, The impact of extracellular matrix on the chemoresistance of solid tumors—experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy, Cancer Lett, 131, 85, 10.1016/S0304-3835(98)00204-3
Smith, 1997, Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi's sarcoma. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR), J Am Acad Dermatol, 36, 239, 10.1016/S0190-9622(97)70288-3
Pillwein, 1998, Hyaluronidase additional to standard chemotherapy improves outcome for children with malignant brain tumors, Cancer Lett, 131, 101, 10.1016/S0304-3835(98)00205-5
Maier, 1989, Metaphylactic effect of mitomycin C with and without hyaluronidase after transurethral resection of bladder cancer: randomized trial, J Urol, 141, 529, 10.1016/S0022-5347(17)40881-0
Klocker, 1998, Hyaluronidase as additive to induction chemotherapy in advanced squamous cell carcinoma of the head and neck, Cancer Lett, 131, 113, 10.1016/S0304-3835(98)00207-9
Yocum, 2007, Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial, J Infus Nurs, 30, 293, 10.1097/01.NAN.0000292572.70387.17
Shepard, 2010, Targeting hyaluronan (HA) in tumor stroma: translational evaluation of pegylated hyaluronidase (PEGPH20, P) in animal models and patients (PTS) with advanced solid tumors
Thompson, 2010, Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models, Mol Cancer Ther, 9, 3052, 10.1158/1535-7163.MCT-10-0470
Baumgartner, 1988, Phase I study in chemoresistant loco-regional malignant disease with hyaluronidase, Regional Cancer Treatment, 1, 55